NCT01309386 - A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Neoplasms

Interventions

DRUG

Tapentadol ER

Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.

DRUG

Morphine SR

Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.

Trial Locations (22)

Chiba

Hamamatsu

Ibaraki

Kanagawa

Katsushika-ku

Kobe

Kumamoto

Matsumoto

Matsuyama

Nagasaki

Nagoya

Nishinomiya

Ohmura

Ohta

Osaka

Saga

Sapporo

Tokyo

Toyama

Toyohashi

Utsunomiya

Yokohama